EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma

by Jie Wang, Zhijie Wang, Jianchun Duan, Rui Wan, Jiachen Xu, Kailun Fei, Chengcheng Li, Wenzhuan Xie, Zhengyi Zhao, Shangli Cai
Published 2020-07-01

Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis

by Puyuan Xing, Fan Zhang, Guoqiang Wang, Yu Xu, Chengcheng Li, Shouzheng Wang, Yiying Guo, Shangli Cai, Yan Wang, Junling Li
Published 2019-12-01

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer

by Teng Li, Han Wang, Jiachen Xu, Chengcheng Li, Yudong Zhang, Guoqiang Wang, Yutao Liu, Shangli Cai, Wenfeng Fang, Junling Li, Zhijie Wang
Published 2021-08-01

Landscape of IDH1/2 mutations in Chinese patients with solid tumors: A pan‐cancer analysis

by Dong Shen, Junling Zhang, Kai Yuan, Jing Zhao, Zhengyi Zhao, Longgang Cui, Yuzi Zhang, Guoqiang Wang, Shangli Cai, Yuezong Bai, Wei Li, Xiang Huang
Published 2021-08-01

TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma

by Wenjing Xiao, Nan Du, Taoyuan Huang, Jinan Guo, Xingkui Mo, Tao Yuan, Yong Chen, Ting Ye, Chunwei Xu, Wenxian Wang, Guoqiang Wang, Shangli Cai, Jing Chen
Published 2018-06-01

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squa...

by Yiting Sun, Jianchun Duan, Wenfeng Fang, Zhijie Wang, Xinyang Du, Xin Wang, Chengcheng Li, Shangli Cai, Jie Zhao, Sini Li, Li Zhang, Hua Bai, Jie Wang
Published 2021-10-01

Association between DNA damage repair gene somatic mutations and immune‐related gene expression in ovarian cancer

by Wenjuan Tian, Boer Shan, Yuzi Zhang, Yulan Ren, Shanhui Liang, Jing Zhao, Zhengyi Zhao, Guoqiang Wang, Xiaochen Zhao, Dongxian Peng, Rui Bi, Shangli Cai, Yuezong Bai, Huaying Wang
Published 2020-03-01

A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer

by Jian Xiao, Wenyun Li, Yan Huang, Mengli Huang, Shanshan Li, Xiaohui Zhai, Jing Zhao, Chan Gao, Wenzhuan Xie, Hao Qin, Shangli Cai, Yuezong Bai, Ping Lan, Yifeng Zou
Published 2021-03-01

Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy

by Fan Zhang, Di Huang, Lei Zhao, Tao Li, Sujie Zhang, Guoqing Zhang, Fang Yuan, Jie Zhang, Yuzi Zhang, Zhengyi Zhao, Longgang Cui, Jing Zhao, Guoqiang Wang, Shangli Cai, Yuezong Bai, Jinliang Wang, Yi Hu
Published 2020-07-01

Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study

by Zhanhong Chen, Yabing Zheng, Wenming Cao, Yuzi Zhang, Zhengyi Zhao, Guoqiang Wang, Jing Zhao, Shangli Cai, Xiying Shao, Jian Huang, Weiwu Ye, Yuan Huang, Wei Li, Xiang Huang, Hao Wu, Xiaojia Wang, Yongmei Yin
Published 2019-09-01